Back to results
US 2023/0414612 A1Published application
Pharmaceutical composition comprising a cap-dependent endonuclease inhibitor
AssigneesTaiGen Biotechnology Co., Ltd., TaiGen Biopharmaceuticals Co.(Beijing), Ltd.
InventorsChung-Shu Hong, Wei-Tsung Chen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a pharmaceutical composition including a solid dispersion containing a cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration.
Claims15
A pharmaceutical composition comprising a solid dispersion, wherein the solid dispersion comprises:
- i) a compound of Formula (II) or a pharmaceutically acceptable salt thereof:
- wherein G is hydrogen or —C(R2R2′)—O—CO—O—R3, in which each of R2, and R2′, independently, is hydrogen or C1-4 alkyl;
- R3 is C1-4 alkyl;
- the star (*) indicates a chiral center;
- and
- ii) a pharmaceutically acceptable polymer,
- wherein a weight ratio of the compound of Formula (II) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is from about 1:1 to about 1:5, and
- wherein the compound of Formula (II) or a pharmaceutically acceptable salt thereof is in a therapeutically effective amount from about 5 mg to about 200 mg.
5 more elements
Dependencies are inferred from the claim text.